Posted Mar. 19, 2013 at 4:15 p.m.

Premium Lock OxyBio weighs options to move TBI drug through trials

Published: 2013-03-19 16:15:06
Updated: 2013-03-19 16:15:06

Oxygen Biotherapeutics Oxygen Biotherapeutics

Oxygen Biotherapeutics' (NASDAQ:OXBT) recent securities offering net $1.9 million -- enough to open clinical trial sites in Switzerland and Israel to study traumatic brain injury drug candidate Oxycyte. Beyond must take other financial steps....

Read More
Read More

WRAL TechWire any time: Twitter, Facebook

Copyright 2017 WRAL TechWire. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL TechWire and WRAL editors. Read more articles…

Please Log In to add a comment.

Latest for Insiders